Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib for Prevention of Cytokine Release Syndrome in IEC Therapy
NCT04071366Phase 2Completed
- Sponsor
- Incyte
- Start
- Feb 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of itacitinib in cytokine release syndrome (CRS) (3 arms), sponsored by Incyte. Primary endpoint: Percentage of Participants Who Developed ≥Grade 2 Cytokine Release Syndrome (CRS) at Day 14. Started Feb 2020; status: completed.
02
Drugs
itacitinib
03
Conditions
cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT04071366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04071366.